Tue.Jun 25, 2024

article thumbnail

Introducing DrugChatter: Revolutionizing Information Access

Drug Patent Watch

DrugChatter is an innovative AI-powered search and answer engine designed to revolutionize how we access and comprehend information. Harnessing the power of advanced natural language processing, DrugChatter provides concise, accurate, and contextually relevant answers to a wide array of questions, making information retrieval faster and more intuitive than ever before.

Engineer 105
article thumbnail

Novavax seeks EMA approval for updated JN.1 Covid-19 vaccine

Pharmaceutical Technology

Novavax has sought EMA approval for its updated JN.1 Covid-19 vaccine, NVX-CoV2705, for people aged 12 years and above.

Vaccine 321
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Exsilio debuts with $82M, pitching a ‘leap’ forward for genetic medicine

Bio Pharma Dive

The company claims it can address some of the field’s limitations with medicines delivered via messenger RNA and lipid nanoparticles.

Medicine 299
article thumbnail

Novo Nordisk invests $4.1bn in manufacturing facility in NC

Pharmaceutical Technology

Novo Nordisk has unveiled a significant investment plan, committing $4.1bn to construct a second fill and finishing facility in Clayton.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

This Rare Gene Variant Seems to Protect You From Alzheimer’s Disease

AuroBlog - Aurous Healthcare Clinical Trials blog

A woman in Colombia with rare genetic resistance to Alzheimer’s disease may have more company than scientists thought.

Gene 241
article thumbnail

Merck KGaA abandons Phase III trial for $1.08bn head & neck cancer drug

Pharmaceutical Technology

Merck’s decision follows the independent committee's analysis that the trial is unlikely to meet its primary endpoints.

Trials 245

More Trending

article thumbnail

Wave, with new data, plots path forward for Huntington’s drug

Bio Pharma Dive

The company plans to make a case to regulators for a new accelerated approval pathway. But investors didn't seem as hopeful, sending shares down by double digits.

article thumbnail

Ethris shares positive data with mRNA drug following new funding    

Pharmaceutical Technology

ETH47 is a type III interferon-encoding mRNA drug that could be used to treat respiratory diseases including uncontrolled asthma.

Drugs 130
article thumbnail

Novo to spend $4B on US plant, adding to obesity drug production push

Bio Pharma Dive

The planned facility in North Carolina is Novo’s latest multibillion-dollar investment in the manufacturing of weight loss drugs, demand for which continues to outstrip supply.

article thumbnail

Pharma packaging solutions, design and companies

Pharmaceutical Technology

Explore the critical aspects of pharma packaging solutions, design, and companies. What to look for to ensure product safety and compliance.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Novo Nordisk wins approval in China for GLP-1 obesity drug Wegovy

Fierce Pharma

On the market for three years in China, Novo Nordisk’s diabetes drug Ozempic (semaglutide) is racing toward blockbuster sales in the world’s second most populous country. | China’s National Medical Products Administration (NMPA) has blessed Novo Nordisk's Wegovy with marketing approval to treat people with a body mass index (BMI) of at least 30 or between 27 and 30 for those with one weight-related risk factor.

Drugs 121
article thumbnail

Medical packaging companies in pharmaceutical contract manufacturing 

Pharmaceutical Technology

Discover the critical factors in choosing medical packaging companies for pharmaceutical contract manufacturing. Ensure quality with our guide.

article thumbnail

Drugmakers dig in their heels amid FTC's latest patent crackdown. What happens next?

Fierce Pharma

In the U.S. Federal Trade Commission’s (FTC) latest campaign against what the agency views as “junk” drug patents listed at the FDA, drugmakers have decided not to play ball. | In the U.S. Federal Trade Commission’s latest campaign against what the agency views as “junk” drug patent listings in the FDA’s database, drugmakers have decided not to play ball.

Drugs 118
article thumbnail

Oncoinvent’s Radspherin has FDA fast-track status for ovarian cancer

Pharmaceutical Technology

Oncoinvent has received FDA fast track designation for its therapy, Radspherin, to treat peritoneal metastases from ovarian cancer.

130
130
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Teva agrees to fork over $750M to close the book on years of tax litigation in Israel

Fierce Pharma

With an agreement to make payments totaling $750 million over the next five years, Teva can wipe its slate clean of litigation from Israeli regulators that concerns over a decade's worth of taxes.< | The deal with the Israel Tax Authority wraps up pending litigation over taxes payable from 2008 to 2020. Crucially, Teva also has to pay additional taxes on any equity dividends or share repurchases.

article thumbnail

GSK’s Omjjara gains approval in Japan for myelofibrosis treatment

Pharmaceutical Technology

GSK has received approval from the Japan's Ministry of Health, Labour and Welfare (MHLW) for Omjjara to treat patients with myelofibrosis.

130
130
article thumbnail

Generative AI in clinical trials: Practical use cases and common concerns

pharmaphorum

Discover practical use cases and common concerns surrounding the implementation of generative AI (GenAI) in clinical trials. Learn how this technology is transforming the landscape of medical research.

article thumbnail

UK’s clinical landscape faces new reality as international competition heats up

Pharmaceutical Technology

At the Outsourcing in Clinical Trials UK and Ireland Conference, prominent figures in UK healthcare highlighted areas for change.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

AbbVie's Duopa successor in Parkinson's rejected again after FDA flags third-party manufacturer issues

Fierce Pharma

A little over a year after being slapped with an FDA rejection, AbbVie has hit another regulatory wall in its bid to debut a more convenient Parkinson’s disease successor to its established fo | A little over a year after being slapped with an FDA rejection, AbbVie has hit another regulatory wall in its bid to debut a more convenient Parkinson’s disease successor to its established formulation of carbidopa and levodopa.

article thumbnail

Cell and gene therapies and the tricky question of patient support

pharmaphorum

Explore the complexities of patient support in the realm of cell and gene therapies. Learn about the challenges and strategies for providing effective patient assistance in this cutting-edge field.

article thumbnail

Glenmark recalls 114 batches of low potassium drug in the US over potentially deadly hyperkalemia risk

Fierce Pharma

While patients with low potassium often need medication to boost levels of the electrolyte in the body, too much of a good thing can cause serious health concerns. | Glenmark Pharmaceuticals on Tuesday said it’s recalling 114 batches of 750mg potassium chloride extended-release capsules thanks to failed dissolution of the product. Failed dissolution of the capsules could cause patients to develop heightened potassium levels, also known as hyperkalemia, which can result in irregular heartbeat.

Drugs 112
article thumbnail

Sugar Reduction Solutions: Meeting the Demand for Healthier Food and Beverages

XTalks

The demand for food and beverage products with less sugar is rapidly increasing. Consumers are becoming more health-conscious, driven by a desire to avoid the negative health impacts associated with high sugar consumption, such as obesity and diabetes. As a result, food manufacturers are under pressure to find effective sugar reduction solutions to meet this demand.

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

Improving connectivity is the route to better health services in the UK

pharmaphorum

Discover how improving digital connectivity can enhance health services in the UK, with a focus on the NHS. Learn about the benefits of embracing digital technology for better healthcare outcomes.

110
110
article thumbnail

Pharma pulse 6/25/24: Novo Nordisk Invests $4.1 billion to Expand US Manufacturing, Improving the Efficacy of Genetic Medicines & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Genetics 105
article thumbnail

Mistrust in healthcare is hitting clinical trial enrolment

pharmaphorum

A survey of pharma industry executives has found that a third of them believe mistrust in the healthcare system has become a significant barrier to getting a diverse range of people to sign up for clinical trials.

article thumbnail

USPTO Study Reveals Trends and Insights into Drug Patent and Exclusivity Trends in the Pharmaceutical Industry

Drug Patent Watch

Introduction: The United States Patent and Trademark Office (USPTO) has recently released a comprehensive study on drug patents and exclusivity trends in the pharmaceutical industry. The report, titled “USPTO Drug Patent and Exclusivity Study Report,” provides valuable insights into the patent landscape, patent duration, and exclusivity trends that shape the pharmaceutical industry.

Drugs 98
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Young adults regret health decisions based on bad info

pharmaphorum

Almost half of young adults who participated in a UK survey said they had made a health decision they regret based on misinformation

105
105
article thumbnail

Scientists uncover new disease-driving mechanism to treat atheroschlerosis

Pharma Times

Atherosclerotic plaques in the arteries affect 42% of adults living without heart disease

article thumbnail

Oral ketamine set for pivotal trials in resistant depression

pharmaphorum

Oral ketamine from Douglas Pharma shows efficacy in phase 2 treatment-resistant depression trial and will move into pivotal trials

Trials 105
article thumbnail

Novo Nordisk's Mim8 significantly reduces bleeds in hemophilia A - plans approval submission

BioPharma Reporter

Once monthly treatment with Novo Nordiskâs antibody treatment reduced annual treated bleeds to zero in 95% previously untreated people with hemophilia A.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.